CD5E Stock Overview
Amundi Index Solutions - Amundi Euro Stoxx 50 is an exchange traded fund launched and managed by Amundi Asset Management.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Amundi Index Solutions - Amundi Euro Stoxx 50 Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$78.99 |
52 Week High | US$80.98 |
52 Week Low | US$65.10 |
Beta | 0 |
1 Month Change | -0.69% |
3 Month Change | 9.86% |
1 Year Change | 14.03% |
3 Year Change | 25.68% |
5 Year Change | 43.93% |
Change since IPO | 41.81% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
CD5E | CH Capital Markets | CH Market | |
---|---|---|---|
7D | 1.6% | -3.2% | -0.9% |
1Y | 14.0% | 27.7% | -4.0% |
Return vs Industry: CD5E underperformed the Swiss Capital Markets industry which returned 27.7% over the past year.
Return vs Market: CD5E exceeded the Swiss Market which returned -4% over the past year.
Price Volatility
CD5E volatility | |
---|---|
CD5E Average Weekly Movement | 1.5% |
Capital Markets Industry Average Movement | 3.2% |
Market Average Movement | 3.5% |
10% most volatile stocks in CH Market | 7.4% |
10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: CD5E has not had significant price volatility in the past 3 months.
Volatility Over Time: CD5E's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | n/a | n/a | n/a |
Amundi Index Solutions - Amundi Euro Stoxx 50 is an exchange traded fund launched and managed by Amundi Asset Management. The fund invests in the public equity markets of the Euro zone. It uses derivatives such as swaps to invest in the stocks of companies operating across diversified sectors.
Amundi Index Solutions - Amundi Euro Stoxx 50 Fundamentals Summary
CD5E fundamental statistics | |
---|---|
Market cap | €13.06m |
Earnings (TTM) | €0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CD5E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CD5E income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €0 |
Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CD5E perform over the long term?
See historical performance and comparison